A Phase 3, Open-label, Multicenter, Pharmacokinetics, Efficacy, and Safety Study of a Recombinant Single-chain Factor VIII (rVIII-SingleChain) in Chinese Previously Treated Patients (PTPs) With Hemophilia A
Latest Information Update: 28 Jan 2025
Price :
$35 *
At a glance
- Drugs Lonoctocog alfa (Primary)
- Indications Haemophilia A
- Focus Pharmacokinetics; Registrational; Therapeutic Use
- Sponsors CSL Behring
- 23 Jan 2025 Planned End Date changed from 26 Feb 2026 to 26 Jun 2026.
- 23 Jan 2025 Planned primary completion date changed from 26 Feb 2026 to 26 Jun 2026.
- 23 Jan 2025 Status changed from not yet recruiting to recruiting.